Comments on: A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Comments on: A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis https://scdstudies.com/a-phase-2multicenteropen-label-study-to-assess-appropriate-dosing-and-to-evaluate-safety-of-crizanlizumabwith-or-without-hydroxyurea-hydroxycarbamidein-sequentialdescending-age-groups-of-pediatri/?utm_source=rss&utm_medium=rss&utm_campaign=a-phase-2multicenteropen-label-study-to-assess-appropriate-dosing-and-to-evaluate-safety-of-crizanlizumabwith-or-without-hydroxyurea-hydroxycarbamidein-sequentialdescending-age-groups-of-pediatri Wed, 19 Jun 2024 12:30:09 +0000 hourly 1 https://wordpress.org/?v=6.7.1